CDKN2A and invasive carcinoma: Our previous studies of human samples and of a mouse model have revealed that serrated polyps and adenomas display high expression of the CDK inhibitor p16INK4a, a characteristic mark for senescence, which is lost in invasive carcinomas by CDKN2A promoter hypermethylation [7, 8, 47, 48].